Cassotide 50 mg (Bicalutamide) Quantity:60 Tablet/s Managing Maintenance Patient Concerns

Managing Maintenance Patient Concerns

\n\nSerious but less common complications can involve interstitial lung disease

but dosage adjustments may be required depending on renal function

Ivermectin 3 mg

Refresh Tear is generally well tolerated due to its preservative-free formulation

Cassotide 50 mg (Bicalutamide) Quantity:60 Tablet/s Managing Maintenance Patient ConcernsProduct Overview Cassotide 50 mg is a prescription oral tablet manufactured by Cipla Limited, containing the active ingredient bicalutamide 50 mg. It is classified as an anticancer agent and is specifically indicated for the treatment of advanced prostate cancer in adult men. The product is supplied in a strip containing ten tablets, each tablet being filmcoated for optimal stability. Cassotide is formulated to provide a consistent systemic exposure